Study finds potential type 2 diabetes aid in Takeda's drug

06/29/2011 | San Francisco Chronicle

A study presented at the annual meeting of the American Diabetes Association found that Takeda Pharmaceutical's TAK-875 drug fared better in reducing the risk of hypoglycemia in patients with type 2 diabetes compared to those in glimepiride and placebo treatments. It was just as effective as glimepiride in lowering hemoglobin A1c.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health